Kymera Therapeutics Inc. (NASDAQ: KYMR) presented positive results from its Phase 1b atopic dermatitis trial of KT-621 at the American Academy of Dermatology Annual Meeting in Denver. The trial evaluated the oral STAT6 degrader in 22 patients with moderate-to-severe atopic dermatitis over 28 days.

The single-arm, open-label trial showed KT-621 achieved median STAT6 reductions of 94% in skin and 98% in blood across 100 mg and 200 mg dose groups. The treatment demonstrated reductions in inflammatory biomarkers including a 74% median reduction in TARC levels, up to 73% reduction of Eotaxin-3, up to 56% reduction of IL-31, and up to 14% reduction of IgE.

Clinical measures showed a mean 63% reduction in EASI scores, with 29% of patients achieving EASI-75 and 19% achieving vIGA-AD scores of 0 or 1. Additional improvements included a 49% reduction in body surface area affected and a 40% reduction in peak pruritus scores. The treatment was described as well tolerated with a favorable safety profile.

Two parallel Phase 2b trials are ongoing: BROADEN2 in atopic dermatitis and BREADTH in asthma, with data expected by mid-2027 and late-2027, respectively. KT-621 represents a targeted protein degradation approach to treating Type 2 inflammatory diseases.

The company reported these findings are based on a press release statement from the clinical-stage biopharmaceutical company, which develops oral small molecule degrader medicines for immunological diseases.